Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Title : Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

Source : PubMed
ID : 30714309
Authors : Boye, Kristina S.; Riddle, Matthew C.; Gerstein, Hertzel C.; Mody, Reema; Garcia-Perez, Luis-Emilio; Karanikas, Chrisanthi A.; Lage, Maureen J.; Riesmeyer, Jeffrey S.; LakshmaNot Specified Mark C
Year : 2019
Disease Category : Cardiovascular diseases
Focused Population : Not Specified
Priori/Posteriori : Both
Single-study Generalibility? : Multiple
Score/Non-Score : Non-score
Tutorial/Method : NHANES_T2D
Compared general demographic and patient characteristics : Yes
Compared disease-specific clinical characteristics : Yes
Compared adverse events : No
Compared outcomes/treatment effect (including survival) : No
Trial participants vs. general population (from EHR, survey, a cohort, etc) : Yes
Participants in different trials : Yes
Real-world data sources : IQVIA Real World Data Adjudicated Claims (United States)
Target Population Data Type Levels : National